Global CRISPR and CAS Gene Market to Surpass US$ 7,603.8 million by 2026

SEATTLE–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/CAS?src=hash" target="_blank"gt;#CASlt;/agt;–According to Coherent Market Insights, the global CRISPR and CAS gene
Market was valued at US$ 1,388.1 million in 2017, and is projected to
exhibit a CAGR of 20.8% during the forecast period (2018 – 2026).

Key Trends and Analysis of the CRISPR and CAS Gene market:

The CRISPR and CAS Gene market size is expected to witness significant
growth rate, owing to increasing research & development along with
increasing demand for clinical trials for the development of new
technologies in CRISPR and CAS gene therapy to treat cancer. For
instance, The Parker Institute for Cancer Immunotherapy, agreed to
sponsor the first in-human clinical trials of CRISPR-enabled technology
targeting three types of cancer. The trial, led by the University of
Pennsylvania, used CRISPR-modified T-cells, a part of the human immune
system, to treat myeloma, melanoma, and sarcoma. The trial was commenced
in 2017.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2598

Moreover, key players are more focused on working in collaborations for
producing novel CRISPR and CAS technology for different therapeutic
areas. For instance, in October 2018 CRISPR Therapeutics and Vertex
Pharmaceuticals’ collaborated for gene-editing clinical trial, to
develop and commercialize new breakthrough therapeutics to cure blood
disorders, and congenital heart disease using the CRISPR/Cas9 technology
to start in the U.S. The trial was scheduled to start by the end of
2018, according to a joint statement from the companies.

To know the latest trends and insights prevalent in this market,
click the link below:

https://www.coherentmarketinsights.com/market-insight/crispr-and-cas-gene-market-2598

Key Market Takeaways:

• The global CRISPR and CAS gene Market is projected to witness CAGR of
  20.8% during the forecast period (2018 – 2026), owing to increasing
  research and development in for different therapeutic area. Research
  institutes are developing gene therapy to cure AIDS. For instance, in
  May 2018, researchers at Kobe University in Japan successfully
  destroyed and deleted the regulatory genes of HIV-1 using the genome
  editing system CRISPR/Cas9, thereby successfully blocking the
  production of HIV-1 by infected cells.
• Among region, North America is expected to show significant growth in
  CRISPR and CAS gene market revenue, owing to increasing research and
  development on CRISPR and CAS gene therapy. In 2017, Editas partnered
  with Juno Therapeutics for cancer-related research using CRISPR under
  the terms of the agreement. Editas has also engaged in a three-year
  research and development (R&D) collaboration deal with San Raffaele
  Telethon Institute for Gene Therapy to research and develop next
  generation stem cell and T-cell therapies for the treatment of rare
  diseases.
• Major players operating in the CRISPR and CAS gene market include
  Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas
  Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc.,
  GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA
  Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene
  Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc.,
  Agilent Technologies, and Applied StemCell, Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting
firm offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.

Contacts

Mr. Shah
Coherent Market Insights
Tel: +1-206-701-6702
Email: [email protected]